June 25, 2020 / 12:09 PM / 10 days ago

BRIEF-Merck KGaA: First Clinical Trial Of TLR7 And 8 Inhibitor As Treatment For Covid-19 Symptoms

June 25 (Reuters) - Merck KGaA:

* INITIATES FIRST CLINICAL TRIAL OF TLR7 AND 8 INHIBITOR AS A POTENTIAL TREATMENT FOR SEVERE SYMPTOMS OF COVID-19 INFECTION

* RESULTS FROM PHASE II STUDY EXPECTED BY END OF 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below